Article: Maxygen and H. Lundbeck A/S Enter Into Research and Development Agreement.

Article: H. LUNDBECK A/S.(signs contract with Maxygen)(Brief ...
Chemical Market Reporter;  September 25, 2000 ;     562 words ...H. LUNDBECK A/S and Maxygen have signed an R&D agreement to develop a protein pharmaceutical product to treat central nervous system diseases, including multiple sclerosis.

Article: Maxygen Reports Third Quarter 2003 Financial Results.
PR Newswire;  October 28, 2003 ;     700+ words ... ... previously licensed to Lundbeck. "Maxygen's optimized interferon ... strategic prioritization of Lundbeck's portfolio, and Maxygen's growing focus and ... agreed to transfer to Maxygen all rights held by Lundbeck with regard to the improved ...

Article: Maxygen Announces Advancement of Human Therapeutics ...
PR Newswire;  October 9, 2001 ;     700+ words ... ... preclinical development in 2001. Maxygen now has four products in its preclinical ... in collaboration with H.S. Lundbeck -- This protein pharmaceutical ... into preclinical development with Lundbeck. Maxygen has retained rights for this compound ...

Article: Maxygen reports first quarter 2002 results.
Hepatitis Weekly;  June 3, 2002 ;     700+ words ... ... are developing with Lundbeck. We believe our product ... Howard, PhD, CEO of Maxygen. "Maxygen currently ... first quarter of 2002, Maxygen unveiled its improved ... development with its partner Lundbeck. Maxygen hopes that this product ...

Article: Maxygen reports first quarter 2002 results.(Brief ...
Vaccine Weekly;  June 5, 2002 ;     700+ words ... ... are developing with Lundbeck. We believe our product ... Howard, PhD, CEO of Maxygen. "Maxygen currently ... first quarter of 2002, Maxygen unveiled its improved ... development with its partner Lundbeck. Maxygen hopes that this product ...

Article: Maxygen Reports Third Quarter 2002 Financial Results.
PR Newswire;  October 29, 2002 ;     700+ words ... ... Including this product, Maxygen is advancing four preclinical ... development with InterMune, Maxygen is developing an improved interferon-beta with Lundbeck for multiple sclerosis that ... manufacturing scale-up. Maxygen also has two wholly-owned ...

Article: Maxygen Reports Second Quarter 2001 Financial Results.
PR Newswire;  August 14, 2001 ;     700+ words ... ... continue to advance Maxygen's broad portfolio ... MS with our partner Lundbeck, allergy with ALK ... industrial applications. Maxygen's technologies bring ... biotechnology products. Maxygen has strategic collaborations ... companies including Lundbeck, ALK-Abello, Shearwater ...